Bionomics (BNOX) Stock Forecast, Price Target & Predictions
BNOX Stock Forecast
Bionomics stock forecast is as follows: an average price target of $6.00 (represents a 3038.08% upside from BNOX’s last price of $0.19) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
BNOX Price Target
BNOX Analyst Ratings
Bionomics Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Dec 19, 2022 | Joshua Schimmer | Evercore ISI | $6.00 | $5.89 | 1.87% | 3038.08% |
Bionomics Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | - |
Avg Price Target | - | - | - |
Last Closing Price | $0.19 | $0.19 | $0.19 |
Upside/Downside | -100.00% | -100.00% | -100.00% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Jun 13, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Mar 10, 2023 | Evercore ISI | - | Outperform | Upgrade |
Dec 19, 2022 | William Blair | Outperform | Outperform | Hold |
Bionomics Financial Forecast
Bionomics Revenue Forecast
Sep 24 | Jun 24 | |
---|---|---|
Revenue | - | - |
Avg Forecast | - | $2.64M |
High Forecast | - | $2.64M |
Low Forecast | - | $2.64M |
# Analysts | - | 1 |
Surprise % | - | - |
Bionomics EBITDA Forecast
Sep 24 | Jun 24 | |
---|---|---|
# Analysts | - | 1 |
EBITDA | - | - |
Avg Forecast | - | $-528.77K |
High Forecast | - | $-528.77K |
Low Forecast | - | $-528.77K |
Surprise % | - | - |
Bionomics Net Income Forecast
Sep 24 | Jun 24 | |
---|---|---|
# Analysts | - | 1 |
Net Income | - | - |
Avg Forecast | $4.23B | $-2.64B |
High Forecast | $4.23B | $-2.64B |
Low Forecast | $4.23B | $-2.64B |
Surprise % | - | - |
Bionomics SG&A Forecast
Sep 24 | Jun 24 | |
---|---|---|
# Analysts | - | 1 |
SG&A | - | - |
Avg Forecast | - | $302.17M |
High Forecast | - | $302.17M |
Low Forecast | - | $302.17M |
Surprise % | - | - |
Bionomics EPS Forecast
Sep 24 | Jun 24 | |
---|---|---|
# Analysts | - | 1 |
EPS | - | - |
Avg Forecast | $2.27 | $-1.42 |
High Forecast | $2.27 | $-1.42 |
Low Forecast | $2.27 | $-1.42 |
Surprise % | - | - |
Bionomics Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
BNOX | Bionomics | $0.19 | $6.00 | 3057.89% | Buy |
PMVP | PMV Pharmaceuticals | $1.64 | $24.75 | 1409.15% | Buy |
ANTX | AN2 Therapeutics | $1.08 | $8.75 | 710.19% | Buy |
AVTE | Aerovate Therapeutics | $2.72 | $13.00 | 377.94% | Hold |
ANEB | Anebulo Pharmaceuticals | $1.89 | $6.00 | 217.46% | Buy |
ACRV | Acrivon Therapeutics | $7.85 | $22.00 | 180.25% | Buy |
RZLT | Rezolute | $5.44 | $13.50 | 148.16% | Buy |
ADAG | Adagene | $3.05 | $5.00 | 63.93% | Buy |
BNOX Forecast FAQ
Is Bionomics a good buy?
Yes, according to 3 Wall Street analysts, Bionomics (BNOX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of BNOX's total ratings.
What is BNOX's price target?
Bionomics (BNOX) average price target is $6 with a range of $6 to $6, implying a 3038.08% from its last price of $0.191. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Bionomics stock go up soon?
According to Wall Street analysts' prediction for BNOX stock, the company can go up by 3038.08% (from the last price of $0.191 to the average price target of $6), up by 3038.08% based on the highest stock price target, and up by 3038.08% based on the lowest stock price target.
Can Bionomics stock reach $0?
BNOX's average twelve months analyst stock price target of $6 supports the claim that Bionomics can reach $0 in the near future.
What are Bionomics's analysts' financial forecasts?
BNOX's analysts financial forecasts for the fiscal year (Jun 2024) are as follows: average revenue is $2.64M (high $2.64M, low $2.64M), average EBITDA is $-529K (high $-529K, low $-529K), average net income is $-2.641B (high $-2.641B, low $-2.641B), average SG&A $302.17M (high $302.17M, low $302.17M), and average EPS is $-1.419 (high $-1.419, low $-1.419).